Black Diamond Therapeutics (BDTX)
Develops brain-penetrant therapies for EGFR-mutant lung cancer and glioblastoma.
$1.89
vs last close−0.09 (−4.59%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 61.28% | 35.21M shares | |
|---|---|---|---|
| 103 holders · as of Jun 30, 2026 | |||
| Insiders | 5.99% | 3.44M shares | |
| 9 holders · as of Sep 21, 2026 | |||
| Other | 32.73% | 18.81M shares | |
| remainder | |||
57.45M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
103 holders · 35.21M shares · 28 new positions · 65 increased · 23 reduced · 32 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Nea Management Company, LLC | 4.45M | 7.74% | 0 | Aug 14, 2026 |
| T. Rowe Price Investment Management, Inc. | 4.03M | 7.01% | −6.53M | Aug 14, 2026 |
| BlackRock, Inc. | 3.92M | 6.82% | +2.81M | Aug 7, 2026 |
| Acadian Asset Management LLC | 2.35M | 4.09% | 0 | Aug 13, 2026 |
| Vanguard Capital Management LLC | 2.13M | 3.70% | +274.8K | Aug 13, 2026 |
| Renaissance Technologies LLC | 1.96M | 3.42% | +318.6K | Aug 13, 2026 |
| Defilade Capital Management, L.P. | 1.67M | 2.92% | +1.67Mnew | Aug 14, 2026 |
| Dimensional Fund Advisors LP | 1.37M | 2.38% | +63.7K | Aug 11, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Ryan Wilderincl. Vestal Point Capital, LP | 8.90% | 5.03M | 13G | Nov 14, 2024 |
| BlackRock, Inc. | 6.70% | 3.84M | 13G | Jul 27, 2026 |
Form 4
Latest trades
No open-market trades in the last 12 months.
House and Senate disclosures
Not reported.